Tapentadol ER

Phase 3Small molecule

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Tapentadol ER is one of 114 small molecule programs targeting Low back pain. It is currently in Phase 3.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Low Back PainActive, not recruiting

Joint DiseaseActive, not recruiting

Chronic PainActive, not recruiting

OsteoarthritisActive, not recruiting

Low Back PainPhase 3

Active, not recruiting

Joint DiseasePhase 3

Active, not recruiting

Chronic PainPhase 3

Active, not recruiting

OsteoarthritisPhase 3

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Tapentadol ER

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 2

Epidiolex

Jazz Pharmaceuticals

Preclinical

4 3

Ilaris

Novartis

Preclinical

2 4

Toradol

Roche

Preclinical

1 5

Bayer Aspirin

Bayer

Preclinical

—6

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 7

Cataflam

Novartis

Preclinical

—8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

1 9

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 10

Catapres

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

A Safety and Efficacy Study of Oral Tapentadol Extended-Release in Japanese Participants

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT01309386·100 enrolled

Chronic pain1 trial

A Study to Evaluate Long-Term Safety of Multiple Doses of Tapentadol (CG5503) Prolonged-Release (PR) and Oxycodone Controlled-Release (CR) in Patients With Chronic Pain

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00361504·1,123 enrolled

Osteoarthritis1 trial

A Study to Evaluate the Efficacy and Safety of CG5503 Prolonged Release (PR) in Subjects With Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee

Completed·GGrünenthal GmbH·Phase 3·NCT00486811·990 enrolled

Low back pain1 trial

A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00449176·981 enrolled

Joint Disease1 trial

A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage Joint Disease

Completed· Johnson & Johnson Pharmaceutical Research & Development, L.L.C. logo

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 3·NCT00784277·597 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Tapentadol ER. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tapentadol ER compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tapentadol ER. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Tapentadol ER

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Safety and Efficacy1 trial

Chronic pain1 trial

Osteoarthritis1 trial

Low back pain1 trial

Joint Disease1 trial

References

Drug Info

Quick Facts

Related News